Stock Financial Ratios, Dividends, Split History

HLI / Houlihan Lokey, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price50.23
Volume171,700.00
Market Cap ($M)1,336.24
Enterprise Value ($M)1,151.27
Book Value ($M)823.90
Book Value / Share30.97
Price / Book1.60
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 66,579,130
Weighted Average Number Of Shares Outstanding Basic 61,100,497
Common Shares Outstanding 23,538,990
Common Shares Outstanding2 43,589,558
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.14
Return on Assets (ROA)0.10
Return on Equity (ROE)0.17
Balance Sheet (mrq) ($M)
Assets1,197.62
Liabilities369.01
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Operating Income182.00
Net Income108.34
Cash Flow Statement (mra) ($M)
Cash From Operations229.26
Cash from Investing-1.65
Cash from Financing-1.65
Identifiers and Descriptors
CUSIP441593100
Central Index Key (CIK)1302215
Related CUSIPS
441593950 441593900

Split History

Stock splits are used by Houlihan Lokey, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Identiv's (INVE) CEO Steven Humphreys on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good afternoon, and welcome to Identiv's Q1 2018 Earnings Call. My name is Devin and I will be your operator this afternoon. Joining us for today's presentation are the company's CEO, Steve Humphreys; and CFO, Sandra Wallach. Following management's remarks, we will open the call for questions. (4-0)

Orix Corporation's (IX) CEO Makoto Inoue on Q4 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Thank you very much for taking time out of your busy schedules to attend ORIX financial results briefing. Let me begin my presentation on consolidated results for fiscal year March 2018. Please refer to Page 2 of the handout. I'd like to start with the trends in net income and ROE. For fiscal year March 2018, net income was ¥313.1 billion, up 15% year-on-year. This represents a record high net income for 4 years in a row, and year-on-year net income growth for 9 years in a row. (4-0)

Houlihan Lokey's (HLI) CEO Scott Beiser on Q4 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good day, Ladies and gentlemen. Thank you for standing by. Please note that this call is being recorded today, May 9, 2018. I would now toll over to Christopher Crain, Houlihan Lokey's General Counsel. Please go ahead. (4-0)

Sainsbury's Asda buy could make UK tougher grocery market for Amazon

2018-05-01 reuters
LONDON (Reuters) - Sainsbury’s (SBRY.L) $10 billion purchase of Walmart’s (WMT.N) Asda may pressure UK grocery prices and make the British market less attractive for newer players such as Amazon.com (AMZN.O). (5-0)

Goldman, hedge funds drawn into Noble’s legal battles

2018-05-01 thestar.com.my
SINGAPORE: Noble Group Ltd’s dissident shareholder Goldilocks Investment Co listed a raft of hedge funds and banks, including Goldman Sachs Group Inc and Deutsche Bank AG, as defendants in its legal battle against the commodity trader, as the fund presses on with a bid to stop its debt-for-equity swap. (73-0)

CUSIP: 441593100